To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of ...

ImmunityBio Executive Chairman Patrick Soon-Shiong criticized the FDA for applying tougher approval standards to Anktiva than to Merck’s Keytruda. ・He said regulators allowed Keytruda to expand across ...

Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...

Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...